arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Burning Rock Biotech Ltd

BNR
$13.26 ▲ +0.37 (+2.87%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
7 Visible periods
4 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Burning Rock Biotech Ltd faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
15
Returns ↑
34
Financial Health ↓
3
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 7 quarters